Every cell in the human body contains that person’s entire genome. This also applies to a tumor cell, except that certain influences drive the occurrence of small or large variations in the genome.  Identifying the unique changes in each patient may help determine the underlying cause of disease and support the development of individualized therapy approaches.

TRON’s driving goal is patient well-being. This motivates us to apply the latest findings and knowledge from our research to future studies. We achieve this using a variety of Next Generation Sequencing (NGS) approaches that enable DNA sequencing in a high throughput process. TRON’s NGS suite therefore uses different combinations of exome sequencing, RNA-Seq, miRNA-Seq, targeted resequencing and / or T-cell receptor sequencing.

The NGS group deals with the design and implementation of new protocols and approaches for high-throughput sequencing. Our scientists have developed specifically adapted sample preparation protocols for sequencing on our Illumina platforms (NovaSeq 6000, HiSeq 2500, MiSeq) and Oxford Nanopore Technologies (MinIon). Together with the Clinical Cancer Genomics group, the methods to screen multi-cellular samples are being adapted to the newest single cell genomics technologies.

The Medical Genomics group represents TRON’s NGS Core Facility. We have specialized in sequencing particularly difficult samples, e.g. formalin-fixed and paraffin-embedded tissue samples (FFPE). All the methods we establish are optimized into standard operating procedures (SOPs), which are followed as part of our internal quality assurance system.